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STUDY QUESTION: Does the intrauterine administration of hCG immediately after oocyte retrieval in antagonist cycles with ICSI and
fresh embryo transfer (ET) inﬂuence the implantation rate or chemical and clinical pregnancy rates?
SUMMARY ANSWER: The intrauterine administration of hCG after oocyte retrieval increases the implantation rate and chemical and clin-
ical pregnancy rates.
WHAT IS KNOWN ALREADY: Over half of IVF/ICSI cycles fail due to implantation failure. Intrauterine administration of hCG, a few
minutes before ET, increased the implantation and pregnancy rates in most but not in all studies. The effect of intrauterine administration of
hCG, after oocyte retrieval, has not yet been studied.
STUDY DESIGN, SIZE, DURATION: The study was a parallel, triple-blind randomized clinical trial (RCT) performed from September
2015 to February 2016, in a university hospital. We recruited women undergoing antagonist ovarian stimulation, ICSI and ET. For an effect
size of 0.2, power of 80% at a signiﬁcance level of 0.05, we needed 150 participants. Accounting for a 7% dropout rate, a total of 160 women
was considered appropriate. A computer-generated randomization list with a block size of 4, with 1:1 allocation was used. The treatment
allocation was placed in a sealed, opaque, envelope and picked up consecutively. Immediately after oocyte retrieval, patients in the interven-
tion and control groups were treated with intrauterine injection of hCG and saline, respectively. Participants underwent ET on Day 3. A beta-
hCG test was done at 2 weeks. If positive, three transvaginal-ultrasonographies (TVSs) were done at 3, 4 and 10 weeks after ET. The partici-
pants were called up thereafter and questioned about the continuity of their pregnancy.
PARTICIPANTS/MATERIALS, SETTING, METHOD: Of 1990 women attending the infertility clinic of our university hospital, 508
were IVF/ICSI candidates during the study period, and 245 of the patients on an antagonist cycle met the criteria to be invited into our trial.
Inclusion criteria were normal ovarian reserve, age ≤41, undergoing ICSI, and fresh ET and normal TSH and prolactin. Uncontrolled chronic dis-
ease, severe hydrosalpinx, severe endometriosis, morphologic embryo deﬁciencies, non-obstructive azospermia and high risk of severe ovarian
hyperstimulation syndrome were criteria for exclusion. After taking an informed consent, a total of 158 participants were recruited, of which 80
were randomly allocated to receive intrauterine 500 IU hCG in up to 0.5ml normal saline and 78 to receive intrauterine 0.5 ml normal saline
immediately after oocyte retrieval, during general anaesthesia. ICSI was performed conventionally. The 4–8 cell embryos were transferred on the
third day after oocyte retrieval. Implantation rate, chemical and clinical pregnancy rates were analysed and compared between the two groups.
MAIN RESULTS AND THE ROLE OF CHANCE: Patients’ demographic and baseline characteristics were comparable. The clinical
results showed statistically signiﬁcant differences between the two groups regarding the biochemical pregnancy rate (59.2 versus 31.3%;
P = 0.001; odds ratio (OR) = 1.88; 95% CI, 1.26–2.82; risk difference (RD) = 27.8; 95% CI, 11.2–42.3), implantation rate (37 versus 17%;
P = 0.012; OR = 2.29; 95% CI, 1.02–5.14; RD = 20.2; 95% CI, 5.4–33.8), clinical pregnancy rate (50.7 versus 16.4%; P < 0.001; OR = 3.08;
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95% CI, 1.71–5.55; RD = 34.3; 95% CI, 18.7–47.6) and ongoing pregnancy rate (40.1 versus 13.4%; P = 0.001; OR = 3.04; 95% CI, 1.55–
5.93; RD = 27.4; 95% CI, 12.7–40.6). The abortion and ectopic pregnancy rates were not statistically different between the two groups.
LIMITATIONS, REASONS FOR CAUTION: The insertion of an intrauterine insemination catheter and the injection of a small amount
of saline into the uterine cavity (without hCG) may also have some impact on implantation. This effect could be studied by comparing this
intervention with another study group without any intrauterine injection.
There are no speciﬁc side effects mentioned in the literature for the intrauterine administration of hCG, neither were any observed in our
study, but it is best to be cautious about probable side effects, because this type of intervention is relatively new and experimental, and
deserves more studies before being entered into routine clinical practice.
WIDER IMPLICATIONS OF THE FINDINGS: Intrauterine administration of hCG immediately after oocyte pick up increases its effect-
iveness; however, further investigations are required before this procedure can be recommended for clinical practice.
STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Women’s Health Research Center, Tabriz
University of Medical Sciences, Iran. No external funds were used. The authors have no conﬂicts of interest to declare.
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Introduction
Implantation failure is the cause of more than half of the pregnancy fail-
ures in ART cycles (Mansour et al., 2011; Wirleitner et al., 2015).
Implantation is a complex process that is regulated by many autocrine
and paracrine factors. hCG is one of the most important of these factors.
Embryos secrete hCG before their implantation (Licht et al., 2007; Cole,
2012; Wirleitner et al., 2015), hCG transcription beginning from the
two-cell stage. It is also produced from the endometrial epithelial cells,
mainly during the luteal phase (Bourdiec et al., 2013b). Using an intra-
uterine microdialysis system to release low concentrations of hCG to the
endometrium in the luteal phase, Licht et al. (2007) showed that hCG
acts before implantation, in an autocrine-juxtacrine manner until its
appearance in the serum. Intrauterine hCG administration modulated
paracrine factors of differentiation (e.g. prolactin, insulin-like growth fac-
tor binding protein-1 (IGFBP-1)) and of implantation (e.g. leukaemia
inhibitory factor (LIF) and macrophage colony stimulating factor
(M-CSF)). Vascular endothelial growth factor (VEGF) and matrix metallo-
proteinase 9 (MMP-9), important for tissue remodelling, were increased
by hCG, suggesting an essential role for hCG in angiogenesis, vasculariza-
tion and placentation of the endometrium (Licht et al., 2001; Cole,
2012). HCG modulates endometrial cell and endothelial cell response to
interleukin1, one of the earliest embryonic signals, and attracts T regula-
tory cells to trophoblasts; so in the endometrium, hCG promotes gene
expression towards implantation, receptivity and tolerance (Cole, 2010,
2012; Bourdiec et al., 2013b; Schumacher et al., 2014).
Using laser capture microdissection, Palomino et al. (2013) demon-
strated that the gene expression levels of endometrial complement C3
and Decay-Accelerating Factor are modulated by intrauterine adminis-
tration of hCG. In addition, crosstalk exists between the intrauterine
hCG signal and the ovarian steroid hormones. These hormones regu-
late the expression of endometrial complement proteins. Therefore,
hCG secreted by the embryo may function as a modulator of embryo-
maternal communication and maternal immune response during
implantation (Palomino et al., 2013; Bourdiec et al., 2013a).
Culturing the embryos in vitro decreases hCG signalling to the endo-
metrium during the early days of the embryo development and could
contribute to the relatively low implantation rate in ART cycles
(Wirleitner et al., 2015; Strug et al., 2016). Many studies have shown
the effectiveness of intrauterine hCG injection before cleavage-stage
embryo transfer (ET) (Mansour et al., 2011; Santibañez et al., 2014;
Zarei et al., 2014). However, others showed no beneﬁcial effect
before blastocyst transfer (Hong et al., 2014; Wirleitner et al., 2015).
The reason could be that with the blastocyst transfer, there is not
enough time for hCG to have any beneﬁcial effect on the endometrium
before implantation (Licht et al., 2007; Strug et al., 2016).
To overcome the limitations of the short duration of the intrauterine
hCG effect before ET, we planned a study to administer intrauterine
hCG earlier than those mentioned in previous studies. Also to bypass
the stress and discomfort of another procedure for the infertile
patient, we supposed that the best time to administer intrauterine
hCG might be immediately after oocyte retrieval, during general anaes-
thesia. Therefore, we designed a study, in fresh antagonist cycles of
IVF/ICSI, to assess the value of intrauterine administration of hCG
after oocyte pick up, on the implantation and pregnancy rates. To
date, there are not any published studies demonstrating the impact of
intrauterine hCG administration immediately after oocyte retrieval on
the outcome of the IVF/ICSI cycles.
Materials andMethods
The study proposal was approved by the ethics committee of our university
centre. From September 2015 to February 2016, 1990 women attended
the infertility clinic of our university hospital, and 508 of them were IVF/ICSI
candidates. A total of 158 of 245 women on an antagonist cycle, who had
the criteria to be included in the trial, accepted our invitation to participate
in the study and signed an informed consent. Inclusion criteria were normal
ovarian reserve (anti-Müllerian hormone ≥0.7 ng/ml), age ≤41 years,
undergoing ICSI and fresh ET and normal level of thyroid stimulating hor-
mone and prolactin. Exclusion criteria were uncontrolled chronic maternal
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diseases like endocrinopathies and autoimmune diseases, severe endometri-
osis, severe hydrosalpinx, non-obstructive azoospermia, high risk for severe
ovarian hyperstimulation syndrome (development of >20 follicles >10mm
at ovarian stimulation or retrieval of >16 oocytes at the day of oocyte
retrieval) (Broer et al., 2013) and morphologic embryo deﬁciencies. All par-
ticipants were on a ﬂexible antagonist protocol (Weissman et al., 2012) for
controlled ovarian stimulation (COS). When at least three follicles ≥17mm
were seen by transvaginal ultrasonography (TVS), ﬁnal oocyte maturation
was triggered by an intramuscular injection of 10 000 IU hCG (Choriomon,
IBSA, Switzerland). Oocyte retrieval was planned 36–40 h later.
Five thousand IU hCG (Choriomon, IBSA) were dissolved in 1 ml dis-
tilled water and stored in the refrigerator at 4°C. For each patient in the
intervention group, 0.1 ml (500 IU hCG) and 0.4 ml normal saline were
pulled into an insulin syringe, and for the patients in the control group,
0.5 ml normal saline. Immediately after oocyte retrieval, during general
anaesthesia, a vaginal speculum was put in place. Any bleeding and clots
were cleaned, and the cervix was visualized. The drug to be injected was
handed to the physician by an operating room technician, who was the
only person who was aware of the patient allocation and the content of
the syringe. The physician injected the solution through an intrauterine
insemination catheter, into the uterine cavity, 1–2 cm above the internal
ostium of the cervix and withdrew the catheter 2 s later. The patient and
the physician were blinded for the type of intervention. The ICSI and ET
were performed conventionally (Magli et al., 2008; Mansour et al., 2011).
The 4–8 cell embryos were transferred on Day 3, after oocyte pick up.
One hundred mg/day of progesterone in oil was administered intramuscu-
larly as luteal-phase support.
We hypothesized that the hCG injection into the uterine cavity after
oocyte retrieval would enhance the endometrial receptivity by triggering
implantation-pathway gene expression.
Participants were asked to perform a pregnancy test at 2 weeks after
ET, and if pregnant, TVSs at 3, 4 and 10 weeks after ET were performed to
detect biochemical pregnancy, gestational sac, fetal cardiac activity and
ongoing pregnancy, respectively. Then, the pregnant participants were
introduced to a prenatal care clinic. At ~14 weeks of pregnancy, we called
up the patients and asked them if they were still pregnant. Our primary
outcomes were biochemical pregnancy, clinical pregnancy and implant-
ation rates. Our secondary outcomes were ongoing pregnancy, abortion
and ectopic pregnancy rates. Biochemical pregnancy was deﬁned by a
beta-hCG rise at 2 weeks after ET. Clinical pregnancy was deﬁned by the
detection of fetal cardiac activity at TVS. Implantation rate was deﬁned by
the number of gestational sacs detected by the ﬁrst TVS after ET per num-
ber of embryos transferred. Ongoing pregnancy rate was deﬁned by a
pregnancy of over 14 weeks. The abortion rate was deﬁned by pregnancy
loss before 20 weeks after ET.
A clinically signiﬁcant increase in implantation was considered to be 20%
(from 15% to 35%), and with a power of 80% and signiﬁcance level of 5%,
a total of 150 women were needed. Accounting for a 7% dropout rate, an
allocation of 80 women in each study group was considered as appropri-
ate. A computer-generated randomization list with a block size of 4 with
1:1 allocation was used to randomize patients. The treatment allocation
was placed in a sealed, opaque envelope and picked up consecutively by
an operating room technician during the oocyte retrieval procedure. She
was the person who was aware of the patient’s allocation, and she also
prepared and handed the intervention drug to the physician. The patient,
the physician and the biomedical statistician were blinded to the group
assignment of the participants.
Statistical analyses
Data were presented as means (SD) and frequencies (%) for numeric and
categorical variables, respectively. The assumption of normality or the
distribution of numeric variables was assessed by the Kolmogorov–
Smirnov test. Independent t-test and Mann–Whitney U test were used for
normally and non-normally distributed variables, respectively. The propor-
tions of desired outcomes (primary and secondary) were compared by
Fisher’s exact test in the two groups. Also, odds ratios (ORs) and risk dif-
ferences (RDs) and their 95% CIs were computed as relative and absolute
effect sizes. In all analyses, P < 0.05 was considered as statistically signiﬁ-
cant (Pocock, 2013). No attempt was made to impute missing data
occurred by dropouts. The analyses were done on a per protocol basis.
Analyses were performed by SPSS 16 software.
Results
A ﬂow chart of patient recruitment is shown in Fig. 1. There was no
statistically signiﬁcant difference in demographic and baseline clinical
characteristics of participants (Table I). The biochemical pregnancy
rate, 42/71 of the participants in the hCG group versus 21/67 of the
participants in the control group (59.2 versus 31.3%; P = 0.001; OR =
1.88; 95% CI, 1.26–2.82; RD = 27.8; 95% CI, 11.2–42.3), the clinical
pregnancy rate, 36/71 of participants in hCG group versus 11/67 of
participants in control group (50.7 versus 16.4%; P < 0.001;
OR = 3.08; 95% CI, 1.71–5.55), and the implantation rate (37% versus
17%; P = 0.012; OR = 2.29; 95% CI, 1.02–5.14) were statistically
greater in the hCG group, compared with the control (Table II).
Pregnancy rates in ﬁrst cycle IVF cases are compared in Table III.
In the hCG group compared with the control group, the abortion
and ectopic pregnancy rates were not statistically different. There was
only one ectopic pregnancy that was in the control group (Table II).
There were no adverse events observed in the study groups.
Because of the three correlated primary outcomes and added false-
positive results, the Bonferroni-adjusted α level (Fleiss, 2011) was cal-
culated equal to 0.017 (0.05/3) and based on this level of signiﬁcance,
all of the differences in primary outcomes would still be statistically sig-
niﬁcant (P < 0.017) (Table II).
Discussion
In this study, we demonstrated that injecting 500 IU hCG in normal
saline into the uterine cavity after oocyte retrieval signiﬁcantly
improved the implantation and pregnancy rates in antagonist cycles
with ICSI and fresh ET. The procedure is simple and practical, because
it is performed immediately after oocyte retrieval under general anaes-
thesia, without additional stress and inconvenience to the patient.
The beneﬁcial effect of hCG on the endometrial receptivity and its
role on the embryo-endometrial crosstalk to promote implantation is
mentioned in multiple studies (Licht et al., 2007; Mansour et al., 2011;
Bourdiec et al., 2013a; Strug et al., 2016). HCG is one of the ﬁrst para-
crine factors secreted by cleavage-stage embryos, and its role for indu-
cing gene expression cascade towards implantation is proposed by
several authors (Banerjee and Fazleabas, 2011; Cole, 2012; Bourdiec
et al., 2013b).
Hyperglycosylated hCG, secreted by cytotrophoblast cells, is the
principal source of early pregnancy hCG. It causes cytotrophoblast
growth and differentiation, increases the capacity of apical cell adhe-
sion, prevents apoptosis and provokes the invasion of the endomet-
rium by metalloproteinases. It increases natural killer cells, inhibits
macrophage migration, antagonizes transforming growth factor beta
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and so modulates maternal immune response, promotes implantation
and establishes a pregnancy (Bourdiec et al., 2013b). hCG plays an
important role in the proliferation of myometrial smooth muscle cells,
reduces cell contractility and increases progesterone receptors. The
hCG/LH receptor genes have been shown in human sperm, Fallopian
tube and uterine spiral arteries, suggesting a role for them in reproduc-
tion (Cole, 2010, 2012).
Strug et al. (2016) demonstrated that ACTA2 and sub-epithelial and
perivascular α-smooth muscle actin expression, critical in preventing
apoptosis and the regulation of the decidual marker IGFBP-1, import-
ant in endometrial receptivity, was induced by intrauterine hCG. Licht
et al. (2007) have also shown that the inhibition of IGFBP-1, which
extends the window of receptivity, is induced by intrauterine infusion
of hCG, that will overcome the luteal-phase defect encountered in fresh
cycles of ovarian stimulation. NOTCH-1 (a member of the NOTCH
transmembrane receptors family) protein expression, an important
determinant of cell survival or fate, required to maintain endometrial
integrity and C3 (which may serve to prime the immune response for
pregnancy) are targets of intrauterine hCG (Strug et al., 2016). Beneﬁcial
effects of intrauterine administration of hCG before cleavage-stage ET
on the outcome of IVF/ICSI cycles have been reported by many authors
(Mansour et al., 2011; Santibañez et al., 2014; Zarei et al., 2014). This
beneﬁcial effect has not been demonstrated for intrauterine hCG
administration before blastocyst stage ET (Hong et al., 2014; Wirleitner
et al., 2015). The drug probably needs more time to effect the endo-
metrium (Licht et al., 2007; Hong et al., 2014) and to reduce the uterine
dyssynchrony and advancement provoked by ovarian stimulations in
ART cycles (Strug et al., 2016).
Wirleitner et al. (2015) studied the intrauterine administration of
500 IU hCG in 40 µl culture media, 2 days and immediately before
blastocyst transfer. They did not notice any beneﬁcial effect for clinical
outcomes in blastocyst transfer cycles. Some points remain to be eluci-
dated in their study. They injected hCG 0.5 cm below the fundus, but
they did not mention at which distance from the fundus they had trans-
ferred the blastocysts. Typically, ET is done much lower, ~1 to 2 cm
below the fundus (Schoolcraft, 2016). However, it is difﬁcult to adjust
ET to the same place after 2 days. The other probable reason of inef-
fectiveness of Day 3 hCG administration in the Wirleitner et al. study
Figure 1 CONSORT ﬂow diagram of patient selection for randomized clinical trial (RCT) of intrauterine administration of 500 IU hCG immediately
after oocyte retrieval on the outcome of ICSI and fresh embryo transfer (ET).
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is the lack of the continuous production of hCG by the embryo
(blastocyst) to sustain the hCG action from Days 3 to 5 (Strug et al.,
2016).
The timing of the intrauterine hCG injection in our study was several
hours before the physiological hCG secretion by the embryo.
Considering the beginning of local hCG production by luteal-phase
endometrium (Bourdiec et al., 2013b), we designed this study to simu-
late the physiological state. We used 500 IU hCG in 0.5 ml normal
saline for intrauterine injections. This volume of injectable solution is
much greater than that used in other studies (20–40 µl) (Mansour
et al., 2011; Hong et al., 2014; Wirleitner et al., 2015). They chose to
inject a much lower volume for intrauterine hCG, because they had to
transfer the embryo a few minutes after the intrauterine hCG injec-
tion, taking into account that the high volume intrauterine injections
might wash out the transferred embryos. Our selected volume for
intrauterine injection is the same as in the Zarei et al. (2014) study.
We administered intrauterine hCG in the early luteal phase, 3 days
before ET, and assumed that by administering this volume, not only
more of the endometrial surface would receive the drug, but also the
drug would have time to provoke the pathway towards, receptivity. It
was not necessary to precisely adjust the place of ET with the location
of the intrauterine hCG injection. Its maximum effect on the prolonga-
tion of the implantation window by the modulation of IGFBP-1 (very
useful in fresh cycles), and provoking the pathway toward implant-
ation, would have been achieved at 48 h after its administration (Licht
et al., 2007; Strug et al., 2016). It is assumed that the effect of intrauter-
ine hCG administered at the time of ovarian retrieval would be contin-
ued by the hCG secreted by the transferred embryos from Day 3
onward (Licht et al., 2007; Strug et al., 2016). Normal saline used in
the control and intervention groups to augment the volume will be
absorbed after 3 days.
Insertion of an intrauterine insemination catheter and the injection
of a small amount of saline into the uterine cavity (without hCG) may
also have some impact on implantation. This effect could be studied by
comparing this intervention with another study group without any
intrauterine injection. Altogether, intrauterine saline injection in our
study seems to have no effect on pregnancy rate, because the out-
comes of the control group are the same as our routine centre out-
comes for the same age group (Table II).
........................................................................................
Table I Baseline characteristics of participants in the
intrauterine 500 IU hCG group, compared with the
control group.a
hCG group
(n = 71)
Control group
(n = 67)
Age (y) 30.6 (7.1) 32 (5.9)
BMI (kg/m2) 27.6 (5.1) 27.3 (5.6)
Infertility duration (y) 8 (1.6) 7.5 (0.9)
Oestradiol level (pg/ml)b 1771.8 (203.5) 2096.6 (161.1)
Progesterone level (ng/ml)b 0.9 (0.1) 1.1 (0.2)
AMH (ng/ml) 1.6 (0.2) 2.1 (0.3)
Endometrial thickness (mm)c 8.7 (1.2) 8.6 (1.2)
Retrieved oocytes (n) 11 (0.6) 12.4 (0.6)
M2 oocytes (n) 9.3 (0.6) 10.1 (0.6)
2pn oocytes (n) 6.9 (1.2) 6.1 (0.3)
High-quality embryos (n)d 3.1 (0.3) 3.7 (0.5)
Fertilization rate (%) 0.6 (0.1) 0.6 (0.1)
Transferred embryos (n) 2.5 (0.8) 2.7 (0.8)
Transferred high-quality embryosd 0.8 (0.1) 0.8 (0.1)
Number of prior IVF cycles, n (%)
0 36 (51) 35 (52)
≥1 35 (49) 32 (48)
Cause of infertility, n (%)
Mixed female and male factors 30 (42) 28 (42)
Male factor 15 (21) 16 (24)
Tubal factor 8 (11) 7 (10)
Ovulatory dysfunction 4 (6) 3 (5)
Endometriosis 6 (9) 3 (5)
Unexplained 8 (11) 10 (15)
aY, years; n, number. Data are mean (SD) unless stated otherwise.
bPeak level at trigger day.
cMeasured at the day of oocyte pick up.
dHigh-quality embryos were deﬁned based on the Istanbul consensus as Grade 1 or
2 and rated Good or Fair (<25% fragmentation, stage-speciﬁc cell size for the
majority of cells, no evidence of multinucleation) (Executive, 2011)
.............................................................................................................................................................................................
Table II Primary and secondary outcomes in the intrauterine 500 IU hCG group compared with the control group.a
hCG group
(n = 71), n (%)
Control group
(n= 67), n (%)
OR (95% CI) RD% (95% CI) P-valueb
Primary outcomes
Chemical pregnancy rate 42 (59) 21 (31) 1.88 (1.26–2.82) 28 (11.2–42.3) 0.001
Fetal cardiac activity 36 (51) 11 (16) 3.08 (1.71–5.55) 34 (18.7–47.6) <0.001
Implantation rate 37% 17% 2.29 (1.02–5.14) 20 (5.4–33.8) 0.012
Secondary outcomes
Ongoing pregnancy ratec 29 (40) 9 (13) 3.04 (1.55–5.93) 27 (12.7–40.6) 0.001
Ectopic pregnancy 1 (1) 0 0.98 (0.95–1.01) 1 (−4.1 to 7.6) 0.514
Abortion rate 6 (9) 7 (10) 0.81 (0.28–2.28) 2 (−12.6 to 8.3) 0.562
aOR = odds ratio; RD = risk difference.
bP-value based on Fisher’s exact test.
cOverall ongoing pregnancy rate during the study period in the centre where the study was run for the same age group was 14%.
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Regarding the lengthy duration of the infertility (~8 years), overall
low AMH levels, the paucity of high-quality embryos and the desire of
our patients, we transferred 2–3 embryos at Day 3, which is one
embryo more than the American Society for Reproductive Medicine
(ASRM) recommendation for that age group. Our high-quality
embryos were deﬁned based on the Istanbul consensus as Grade 1 or
2 and rated Good or Fair (<25% fragmentation, stage-speciﬁc cell size
for the majority of cells, no evidence of multinucleation) (Executive,
2011). The statistically signiﬁcant differences between the outcomes of
our two study groups show the beneﬁcial effect of intrauterine hCG,
speciﬁcally on the implantation of non-top embryos with low capacity
of hCG secretion in fresh cycles of IVF/ICSI.
The overall low rate of ongoing pregnancy in our control group
(14%) may reﬂect the characteristics of our patients including lengthy
duration of the infertility (~8 years), overall low AMH levels and the
paucity of top quality embryos, which are representative of our overall
institute’s attendees. Accordingly, our ongoing pregnancy rate for the
same age group at the time period of the trial was the same as our
control group, lower than the general practice.
Although there is no speciﬁc side effect mentioned in the literature
for the intrauterine administration of hCG, it is best to be cautious
about the probable side effects of this relatively new and experimental
intervention. Theoretically, the local increase of growth factors and
the modulation of the immune system may increase the susceptibility
for local neoplasia and infection. In the present study, we did not
observe any side effects, but obviously longer follow-up is needed to
assess potentials hazards.
Statistical limitations
Because of the correlated primary outcomes, we had multiple testing
and added false-positive rates in our tests regarding these outcomes.
To accommodate with our sample size calculation and the power of
the tests, we kept α level equal to 0.05. However, for the three corre-
lated primary outcomes, the Bonferroni-adjusted α level (Fleiss, 2011)
is equal to 0.017 (0.05/3) and based on this level of signiﬁcance, all of
the differences in primary outcomes would still be statistically signiﬁ-
cant (P < 0.017) (Table II).
In this RCT, we demonstrated that intrauterine administration of
500 IU of hCG during general anaesthesia after oocyte retrieval could
effectively increase the implantation and pregnancy rates. The novelty
of the timing of the hCG injection following ovarian retrieval in this
study mandates further studies before recommending its routine use
in clinical practice.
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